Company Overview and News

 
DHFL stock cracks 42%; here#39;s what MD Kapil Wadhawan has to say about it

2018-09-21 moneycontrol
Dewan Housing Finance Corporation (DHFL) share price plunged as much as 60 percent to hit fresh 52-week low of Rs 246.25 amid high volumes, but managed to trim a bit of losses on Friday.
GRUH 511072 IDKQY GRHFY 535322 CANFINHOME 532978 511196 SRTRANSFIN 511288 REPCOHOME 511218 535789 IBULHSGFIN DHFL BAJAJFINSV BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 500253 500034

 
DHFL stock cracks 60% to below Rs 300; here#39;s what MD Kapil Wadhawan has to say about it

2018-09-21 moneycontrol
Dewan Housing Finance Corporation (DHFL) share price plunged as much as 60 percent to hit fresh 52-week low of Rs 246.25 amid high volumes on Friday.
GRUH 511072 IDKQY GRHFY 535322 CANFINHOME 532978 511196 SRTRANSFIN 511288 REPCOHOME 511218 535789 IBULHSGFIN DHFL BAJAJFINSV BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 500253 500034

 
DHFL stock halves to trade below Rs 400, other housing finance firms also follow suit

2018-09-21 moneycontrol
Dewan Housing Finance Corporation (DHFL) share price plunged 42.5 percent to hit fresh 52-week low of Rs 351.05 amid high volumes on Friday.
GRUH 511072 IDKQY GRHFY 535322 CANFINHOME 532978 511196 SRTRANSFIN 511288 REPCOHOME 511218 535789 IBULHSGFIN DHFL BAJAJFINSV BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 500253 500034

 
Repco Home Finance Limited - Updates

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535322 REPCOHOME

 
Repco Home Finance sets up satellite centre at Sri City

2018-08-24 moneycontrol
City based Repco Home Finance has inaugurated a satellite centre at neighbouring Sri City Special Economic Zone under its expansion drive. Repco Home Finance Ltd, Chairman and former Chief Election Commissioner T S Krishna Murthy unveiled a plaque at Sri City, about 100 km from here, recently.
535322 REPCOHOME

 
Repco Home Finance Limited - Updates

2018-08-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535322 REPCOHOME

 
Repco Home Finance Limited - Investor Presentation

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535322 REPCOHOME

 
Repco Home Finance Limited - Updates

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535322 REPCOHOME

8
Will compulsory delivery impact F&O trading?

2018-06-29 thehindubusinessline
KS Badri Narayanan Be prepared to have enough money in your account if you want to trade in the 46 F&O stocks that have been moved to the compulsory delivery category by the NSE starting July. This follows the SEBI diktat in March to align the cash and derivative segments of the market, through physical settlement for all stock derivatives in a phased and calibrated manner. To start with, the NSE has initiated compulsory delivery in 46 stocks.
SRI 532939 SREINFRA GODREJIND 533096 UBL IDBI 532899 532712 532478 533106 JUSTDIAL GRANULES 535648 RCOM OIL 532482 KSCL DCBBANK RPOWER SIFLY 523756 ALNSE 500116 UBHOLDINGS 535322 SRIA UNBWY REPCOHOME 532772 ADANIPOWER 507458 500164 JSTQY

17
MFs offloaded shares in PowerGrid, InterGlobe Aviation in May

2018-06-20 thehindubusinessline
Suresh P Iyengar The mutual fund industry has offloaded 22 per cent of Power Grid Corporation shares worth ₹1,905 crore in May, as prospects of the company looked bleak with no major new power project being launched and a sharp decline in power generation.
RIFS 532617 HCTHY TTQQY TATACHEM 500390 PIDILITIND PDLTY 532281 HDFCBANK 500770 500331 INDIGO RELEY IBN RELFF JETAIRWAYS 535322 REPCOHOME 539448 RELINFRA ICICIBANK HDB 532174 500180 HCLTECH RIFA 534809 PCJEWELLER

 
Analysts see tough days ahead for housing finance companies

2018-06-08 thehindubusinessline
Our Bureau Share prices of housing finance companies will remain under pressure on margin concerns due to rising bond yields, say analysts.
GRUH GICHSGFIN DHFL 511072 LICHSGFIN GRHFY 535322 LHFLY 511676 500253 511288 REPCOHOME

 
Repco Home Finance Limited - Updates

2018-06-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535322 REPCOHOME

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...